Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
South Korea Financing Companies

Korean Bioventure Financing Continues Downward Spiral In Q3

Handful Of IPOs Amid Chilly Sentiment

  • Analysis

Executive Summary

VC Investment in South Korea’s biopharma sector drops again as investors continue to shy away amid higher interest rates and reduced out-licensing deals.

You may also be interested in...



Will The Dark Tunnel For Korean Biopharmas End In 2023?

Scrip wraps up major R&D and corporate developments for Korean biopharmas in 2022 and outlines what lies ahead for them in the new year.

Korean Biotech IPOs Fall In Tough Environment But Brighter Outlook Ahead?

Several innovation-based Korean bioventures, including GI Innovation, S.Biomedics and Curocell, have managed to launch IPOs in 2023 despite prolonged depressed market sentiment and tougher stock exchange rules.

New Korea Commission Needs Status To Function As Control Tower: Industry

A policy report by a major South Korean pharma industry association puts forward suggestions on what it will take for a new pan-government control tower to function properly.

Table

View full table

Topics

Related Companies

Tags:
South Korea Financing Companies
Latest Headlines

Radiopharmaceutical Leader ITM Gets A Burst Of Energy – And Weighs Up Going Public

Efficacy, Not Safety, Does For Merck KGaA’s BTK Inhibitor

AstraZeneca Likes What Chinese Innovation Has To Offer

Astellas Exec On Tech Tools For Better Go-No-Go Decisions, Gen AI

See All
UsernamePublicRestriction

Register

SC147427

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By